Advertisement
UK markets close in 2 hours 12 minutes

  • FTSE 100

    8,066.64
    +26.26 (+0.33%)
     

  • FTSE 250

    19,648.07
    -71.30 (-0.36%)
     

  • AIM

    754.00
    -0.69 (-0.09%)
     

  • GBP/EUR

    1.1664
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2464
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    50,578.43
    -2,519.89 (-4.75%)
     

  • CMC Crypto 200

    1,350.98
    -31.59 (-2.28%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.55
    -0.26 (-0.31%)
     

  • GOLD FUTURES

    2,337.70
    -0.70 (-0.03%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,897.33
    -191.37 (-1.06%)
     

  • CAC 40

    7,981.32
    -110.54 (-1.37%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Can Walgreens Succeed in This Market Where CVS Failed?

Alex Carchidi, The Motley Fool
·4-min read
Can Walgreens Succeed in This Market Where CVS Failed?

When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?

Continue reading